Share This Page
Drugs in ATC Class B01AF
✉ Email this page to a colleague
Drugs in ATC Class: B01AF - Direct factor Xa inhibitors
| Tradename | Generic Name |
|---|---|
| RIVAROXABAN | rivaroxaban |
| XARELTO | rivaroxaban |
| ELIQUIS SPRINKLE | apixaban |
| ELIQUIS | apixaban |
| APIXABAN | apixaban |
| SAVAYSA | edoxaban tosylate |
| >Tradename | >Generic Name |
rket dynamics and patent landscape for ATC Class B01AF: direct factor Xa inhibitors (oral anticoagulants)
Direct factor Xa inhibitors in ATC B01AF are dominated by apixaban, rivaroxaban, edoxaban, and betrixaban in approved markets. Patent protection is primarily driven by (i) composition-of-matter for the active and key salts, (ii) formulation patents for tablets, film coatings, and specific release profiles, and (iii) process/manufacturing patents that can block generic entry even after core drug substance coverage ends. Near-term competitive pressure comes from the spread between drug substance expiration and regulatory exclusivities (where applicable), plus the time needed to clear FDA Orange Book-linked listed patents via Paragraph IV or licensed carve-outs.
Which direct factor Xa inhibitors are in ATC B01AF and who sells them today?
ATC B01AF is the direct factor Xa inhibitor class and includes oral factor Xa inhibitors. The core market is currently secured by apixaban and rivaroxaban; edoxaban is established in specific geographies/indications; betrixaban remains a smaller category product.
Key drugs (ATC B01AF) and primary commercial positioning
| Active ingredient | Product examples | Core indications (high level) | Main competitive set |
|---|---|---|---|
| Apixaban | Eliquis (BMS/Pfizer) | Stroke prevention in AF; VTE treatment/prophylaxis depending on label | Generic apixaban + remanufactured/authorized generics; biosimilar concepts not applicable (small molecule) |
| Rivaroxaban | Xarelto (Janssen/Bayer) | AF stroke prevention; VTE treatment/prophylaxis; other labeled settings | Generic rivaroxaban; competing factors with different dosing/label scope |
| Edoxaban | Savaysa (Daiichi Sankyo) | AF stroke prevention (select patients); VTE treatment/prophylaxis by label | Generic edoxaban in markets where supply chains allow |
| Betrixaban | Bevyxxa (Portola, now Acquired/partnered depending on jurisdiction) | Extended VTE prophylaxis in some hospital populations | Smaller-volume competition; class competition from apixaban/rivaroxaban |
Market dynamic (business framing): the category’s economics are driven more by label breadth, dosing convenience, and formulary placement than by incremental patent-covered tweaks. Patent estates primarily influence when generics can launch and which specific dosage strengths or formulation variants can be sold.
What patents protect ATC B01AF direct factor Xa inhibitors (composition, formulations, and methods of use)?
For each drug, patent estates typically separate into three buckets that map to generic design freedom:
- Drug substance (composition-of-matter) patents: cover the compound or specific salt forms and related chemical families. These usually control the earliest exclusivity boundary.
- Formulation and delivery patents: cover tablet design, film coating, disintegration profile, specific excipient systems, or targeted release mechanics (where relevant).
- Processes/manufacturing patents: cover synthesis steps, purification conditions, crystallization, polymorph control, and solvent residues. These can remain listed and litigated even after drug substance patents age out.
Patent estate architecture by coverage type
| Patent coverage type | What it blocks | Why it matters for generics | Where it shows up |
|---|---|---|---|
| Composition-of-matter | The active compound/salt family | Prevents FDA approval unless a carve-out license or Paragraph IV success | Orange Book listing(s) tied to NDA |
| Formulation (tablet, coatings, release) | Specific dosage strength/product design | Enables “design-around” or creates additional infringement triggers | Orange Book often lists multiple formulation patents |
| Method-of-use | Specific regimen/clinical claims | Can block an NDA for a label-indistinguishable product | More relevant in label-narrowed indications |
| Process/manufacturing | Production of the active ingredient | Generic may still face an infringement claim for the manufacturing route | Litigation in US and EPO-style enforcement |
How strong is the patent estate for apixaban, rivaroxaban, and edoxaban?
In direct factor Xa inhibitors, “strength” is best measured by (i) count of Orange Book listed patents still in force, (ii) history of Paragraph IV litigation and outcomes, and (iii) whether settlement agreements preserve exclusivity or carve out launches.
How to read “strength” in practical terms
- More Orange Book listed patents for the same NDA typically means more potential infringement hooks, higher litigation cost, and greater likelihood of settlements that delay launch.
- Multiple patent categories (drug substance + formulation + process) reduce the chance that a generic can win on a single patent.
- Settlement structures often show which patents are commercially critical. If settlements repeatedly hinge on specific strengths or dates, those patents remain value drivers.
When does direct factor Xa inhibitor exclusivity end and when can generics launch?
Exclusivity is not a single date. It is a stack:
- FDA regulatory exclusivity (new chemical entity or new molecular entity exclusivities, where applicable at NDA level)
- Patent expiration for Orange Book listed patents
- Hatch-Waxman timing: 180-day exclusivity for first Paragraph IV filer (where triggered)
- Settlement agreements that can extend practical “launch windows” beyond hard expiration dates
Category-level timing pattern (what market participants watch)
| Timing lever | Typical market effect | Why it matters to planning |
|---|---|---|
| NDA regulatory exclusivity | Delays generic submission/approval in practice | Drives negotiating leverage |
| Patent expiration | Enables Section viii statement or carve-out strategies | Sets expected launch window |
| 180-day exclusivity | Locks up first-generic entry | Determines whether multiple generics race or wait |
| Settlement | Extends exclusivity beyond statutory dates | Moves actual launch and inventory planning |
What Orange Book status and listed patents exist for Eliquis (apixaban) and how do they affect generic entry?
In the US, apixaban’s generic timeline is governed by the remaining Orange Book listed patents associated with the Eliquis NDA(s). The generics strategy is typically either:
- Paragraph IV certifications against listed patents, aiming for a launch at the earliest legal date, or
- Carve-out licensing (via settlement) tied to specific patents, strengths, or label coverage.
Orange Book-driven entry dynamics
- If multiple formulation/process patents remain, a generic must either challenge them (risking losses) or negotiate a settlement carve-out.
- If the generic’s certification triggers multiple infringement allegations, litigation can extend beyond the earliest patent expiration because courts may address multiple patents on overlapping schedules.
Business implication: even when composition-of-matter patents have aged out, formulation and process patents can preserve entry friction for years.
Which patents cover Xarelto (rivaroxaban) and what litigation patterns determine launch timing?
Rivaroxaban’s US market access has historically been shaped by:
- Dense Orange Book listings for multiple strengths.
- Patent-by-patent challenges that often lead to multi-issue settlements.
- Enforcement actions that can focus on formulation or manufacturing route infringement rather than only drug substance chemistry.
Typical Paragraph IV playbook for rivaroxaban
- File an ANDA with Paragraph IV certifications for selected listed patents.
- Challenge patents they believe are weak or easily designed around.
- Set readiness for launch but condition commercial rollout on final court decisions and settlement terms.
Market dynamic: rivaroxaban’s large revenue base usually attracts multiple generic filers, increasing the likelihood of first-filer 180-day dynamics and settlement bargaining.
What is the patent landscape for Savaysa (edoxaban) and how does it compare with apixaban and rivaroxaban?
Edoxaban is in the same ATC class but tends to have:
- Smaller volume base in the US compared with apixaban/rivaroxaban.
- A patent estate that still can include multiple listed patents per dosage form, but fewer generics may aggressively race for each strength.
Comparison logic
| Attribute | Apixaban | Rivaroxaban | Edoxaban |
|---|---|---|---|
| Market size and generic interest | Highest | High | Moderate |
| Settlement intensity | Often high due to value and multiple listings | High | Usually lower, but still material at key strengths |
| Strategy focus | Multiple patents often require multi-front resolution | Dense filings and stronger settlement leverage | Usually fewer entrants, but still depends on remaining formulation/process patents |
What biosimilar or biologics risks apply to direct factor Xa inhibitors?
None. Direct factor Xa inhibitors in ATC B01AF are small molecules. Competition risk is from generics and authorized generics, not from biosimilars.
Which formulations of direct factor Xa inhibitors face the most patent barriers?
For oral small-molecule anticoagulants, formulation patents are often the last mile. Patents can cover:
- Immediate-release tablet designs (apixaban, rivaroxaban typical forms are immediate-release)
- Specific excipient systems that drive dissolution and bioavailability
- Coating and manufacturing parameters affecting stability and release
- Strength-specific formulations that appear as separate listed patents
Practical barrier types that block “easy entry”
- Different excipient compositions by strength that create distinct infringement issues.
- Crystallinity/polymorph control in manufacturing that triggers process patent claims.
- Coating procedures and film thickness parameters captured in manufacturing patents.
How do method-of-use and regimen patents affect label-generic competition?
Method-of-use patents can complicate entry if they cover:
- A labeled dosing regimen that differs from the generic’s intended use.
- Specific patient subpopulations or clinical endpoints that map onto claims.
For label-identical generics, method-of-use patents can create “non-infringing labeling” constraints. Even without active substance infringement, method-of-use can keep a generic off-label until litigation resolves.
Which companies are challenging ATC B01AF patents via Paragraph IV?
At a category level, the challenge set usually includes:
- Large generic firms (multiple ANDA filings per molecule).
- Specialty generics and launch-focused players for selected strengths.
- “Carve-out” settlement counterparties that align with the first-filer 180-day dynamic.
Business implication: multiple filers increase the probability that at least one can trigger 180-day exclusivity, raising brand leverage to negotiate settlements that trade away litigation risk for delayed entries.
(Note: a molecule-by-molecule company list requires molecule-specific Orange Book and litigation docket extraction, which is not provided in the input.)
What patent litigation affects apixaban and rivaroxaban launches most?
Litigation typically clusters into:
- Validity challenges to composition and formulation patents.
- Infringement disputes tied to manufacturing process and product dissolution/bioequivalence evidence.
- Settlement-driven timing where courts do not decide every contested patent, but parties agree to a launch schedule.
How litigation outcome translates into market timelines
| Litigation outcome type | Commercial translation |
|---|---|
| Patent upheld | Generic launch delayed to patent expiration |
| Patent invalidated | Faster entry for the relevant patent(s), subject to other listed patents |
| Settlement | Launch allowed on negotiated date, sometimes with strength-specific limitations |
| Design-around accepted | Generic may launch but with narrower formulation/label commitments |
Which settlement agreements and licensing deals most influence the category?
For major brands (apixaban/rivaroxaban), settlements usually:
- Predefine launch dates per strength.
- Tie entry to the outcome of remaining contested patents.
- Include non-monetary constraints such as labeling and marketing restrictions.
Category-level dynamic: licensing settlements can shift “effective exclusivity” beyond statutory patent expiration due to staggered dates by strength and manufacturing route.
What is the FDA regulatory status and approval pathway for generics in ATC B01AF?
Generics for these small molecules typically use:
- ANDAs under the Hatch-Waxman framework.
- Paragraph IV certifications for Orange Book listed patents if seeking early launch.
- 505(b)(2) or 505(j) pathways for certain reformulations or distribution changes in some cases (but core generic competition is ANDA-based).
Market planning lens: filings near key patent expirations are scheduled to maximize the earliest permissible approval date, then followed by launch readiness (inventory, contracting, distribution).
How does ATC B01AF competition compare with other anticoagulants (DOACs and warfarin)?
Within DOACs, competition is mostly:
- Between factor Xa inhibitors (B01AF) and thrombin inhibitors (ATC B01AE) and VKAs (warfarin).
- Formularies and payer negotiations determine relative uptake more than marginal patent expiration effects.
Business dynamic: patent-driven generic entry affects brand pricing and volume capture, which then changes payer incentives across the anticoagulant class.
What generic entry risks exist for direct factor Xa inhibitors?
Key risks for generic entrants include:
- Losing Paragraph IV litigation on one or more key listed patents.
- Delays tied to settlement terms that cap entry date.
- Non-infringement challenges failing because the generic product matches dissolution/bioequivalence characteristics that align with formulation claims.
- Process patent exposure if the generic cannot prove a non-infringing manufacturing route.
Key takeaways
- ATC B01AF direct factor Xa inhibitors are small molecules dominated by apixaban and rivaroxaban; market dynamics are driven by Orange Book-linked patent density and settlement outcomes, not by biosimilar competition.
- Patent protection spans composition-of-matter plus formulation and manufacturing/process patents; formulation and process coverage often controls “last-mile” generic launch timing.
- Exclusivity is a stack of regulatory exclusivity, patent expiration, Hatch-Waxman timing, and settlement schedules; practical launch dates often reflect settlements and strength-by-strength carve-outs.
- Competitive pressure is primarily generic entry (ANDAs) and authorized generics after patent and litigation resolution.
FAQs
1) What patents delay generic apixaban beyond the drug substance expiration date?
Formulation and process/manufacturing patents tied to specific strengths often remain the last litigated Orange Book items.
2) How does 180-day Paragraph IV exclusivity influence the timing of generic entry for rivaroxaban?
It can accelerate approval of the first successful challenger while increasing settlement leverage for the brand.
3) Are biosimilar risks relevant for factor Xa inhibitors in ATC B01AF?
No. These are small molecules; competition is from generics and authorized generics.
4) Why do formulation patents matter even when generic bioequivalence is achieved?
Bioequivalence can coexist with product design or manufacturing practices that infringe formulation or process patents.
5) What factors most affect settlement dates for DOAC generics?
The number of remaining Orange Book listed patents, strength coverage, and the specific patents brands consider commercially “critical” in court filings.
References (APA)
No sources are cited because the provided input does not include Orange Book listings, patent numbers, litigation dockets, or FDA milestones to support molecule-specific citation-grade assertions.
More… ↓
